Sigi Neerken

Sigi Neerken is a co-founder of InnoSIGN, a Dutch medtech startup that spun out from Philips in 2022. At InnoSIGN, Neerken is involved in commercializing its proprietary mRNA-based OncoSIGNal pathway activity profiling technology, which was developed by scientists at Philips Research. The company aims to revolutionize precision medicine by providing insights into disease mechanisms and predicting patient responses to targeted drugs.